menu
    • menu
    [{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"AMTX-100","moa":"SRTFs","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Amytrx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ AmbioPharm"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AMTX-100 CF3","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Amytrx Therapeutics

    Menu

    Amytrx Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100 CF3

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Amarex Clinical Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-In...

                            Details : AMTX-100 CF3, is a topical formulation anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis.

                            Brand Name : AMTX-100 CF3

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : AMTX-100 CF3

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Amarex Clinical Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AmbioPharm

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Its Breakthrough Leukocyte-Targeting A...

                            Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.

                            Brand Name : AMTX-100

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AmbioPharm

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Amarex Clinical Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis

                            Details : AMTX-100 CF3, its leading drug candidate, is known for its ability to transport across membranes, address inflammation and modulate immune mediated diseases instead of simply inhibiting inflammation.

                            Brand Name : AMTX-100

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Amarex Clinical Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $18.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Raises $18M For New Therapeutic Interventions of Atopic Dermatitis

                            Details : The funding is dedicated to continuing clinical research on the use of their next-generation anti-inflammatory therapeutic peptide platform, AMTX-100, across several skin inflammatory disorders in adults and adolescents.

                            Brand Name : AMTX-100

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            May 25, 2022

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $18.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Amytrx Therapeutics

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Progra...

                            Details : Amytrx is developing AMTX-100, a new anti-inflammatory therapeutic platform, which has broad potential in multiple inflammatory, autoimmune, and metabolic diseases.

                            Brand Name : AMTX-100

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 17, 2020

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth